Clinical Usefulness of Bronchoalveolar Lavage in the Management of Pulmonary Infiltrates in Adults with Hematological Malignancies and Stem Cell Transplantation
Division of Infectious Diseases, Centro de Educación Médica e
Investigaciones Clínicas “Norberto Quirno” (CEMIC), Buenos Aires,
2 Department of Medicine, Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno” (CEMIC), Buenos Aires, Argentina.
3 Pulmonary Medicine Section, Department of Medicine, Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno” (CEMIC), Buenos Aires, Argentina.
4 Department of Microbiology, Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno” (CEMIC), Buenos Aires, Argentina.
5 Clinical Virology Laboratory, Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno” (CEMIC), Buenos Aires, Argentina.
Received: February 5, 2020
Accepted: April 4, 2020
Mediterr J Hematol Infect Dis 2020, 12(1): e2020025 DOI 10.4084/MJHID.2020.025
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Pulmonary complications are frequent in patients with hematologic
malignancies and stem cell transplantation. Regardless of the
microbiological usefulness of bronchoalveolar lavage (BAL), little
information exists on both its benefits as a guide for therapeutic
decisions and its impact on patients’ clinical outcome.
In addition to invasive methods,[7,8] microbiological non-invasive diagnostic tests, such as sputum culture, nasopharyngeal swab for respiratory virus detection and a serologic test for fungal and viral detection, have shown diagnostic usefulness, especially in patients with respiratory failure where bronchoalveolar lavage (BAL) performance may be harmful due to unstable clinical setting.[9,10]
Bronchoalveolar lavage fluid analysis has been widely used as a diagnostic tool for the diagnosis of pulmonary infiltrates (PI) in immunosuppressed patients, with a variable diagnostic yield among different series (31-80%).[11-15] However, there is scarce robust evidence for its usefulness as a tool for therapeutic decision-making (even with positive microbiological culture results) and its impact on patients’ outcome and continues to be investigated.[6,12,16,17,18]
The main purpose of the present study was to describe the etiology of PI in patients with hematological malignancies under chemotherapy or stem cell transplantation. Secondary objectives were to assess BAL diagnostic yield and usefulness as a therapeutic decision approach, and finally to describe BAL safety in this subset of patients.
According to the treating physician´s best judgment, non-invasive (sputum culture, nasopharyngeal swab for respiratory virus detection, urinary pneumococcal antigen, serum galactomannan index, blood cultures, cytomegalovirus (CMV) viral load) and/or invasive (BAL, transbronchial lung biopsy, surgical lung biopsy) diagnostic methods were performed. BAL was performed under propofol or remifentanil sedation through laryngeal mask access with mechanical ventilation support. Lavage was performed using six 20ml saline solutions syringes. Our routine microbiological research for BAL fluid consists of culture for bacteria, Nocardia, mycobacteria and fungi, galactomannan index, PCR, and shell vial detection for CMV and Gram Weigert’s technique for Pneumocystis jirovecii detection. Respiratory syncytial virus (RSV), adenovirus, Influenza A and B, and parainfluenza (1-3) diagnosis by direct antigen detection by immunofluorescent assay with monoclonal antibodies (Millipòre) in smears of respiratory samples. RSV, human metapneumovirus, adenovirus, rhinovirus, and Influenza A detection by real-time PCR: nucleic acid was extracted by total nucleic acids from 200 ul of the original sample using the automated MagNA Pure LC 2.0 with the MagNA Pure Compact Nucleic Acid Isolation Kit I extraction kit from Roche. Real-time PCR was performed with 5ul of nucleic acid eluate using for Influenza A/H1N1, adenovirus, and human metapneumovirus commercial assay set (TibMolbiol, Roche) and the enzyme LightCycler Multiplex RNA Master Virus in the Light Cycler 2.0 device as manufacturer’s instruction. For RSV and rhinovirus detection, a homebrew real-time PCR was used.[19,20] The same viral detection techniques were used for nasopharyngeal swab samples. The serum galactomannan index was performed by enzyme immunoassay (PlateliaâAspergillus Bio-Rad, France) and considered positive with two independent samples ≥0.5 optical density index value. Instead, positive BAL fluid was considered positive, with one sample ≥1 optical density index value. Early BAL was defined as the one performed within 4 days after the diagnosis of PI.[6,22] Patients were followed for 30 days after the diagnosis of PI.
Predominant abnormal radiologic patterns were defined as uni or bilateral alveolar consolidation, nodular, “ground glass” opacity, or “tree-in-bud” pattern, according to radiologists’ descriptions. The presence or absence of pleural effusion was also recorded.
Etiologies of PI were classified as either infectious or non-infectious. Infectious etiologies could be bacterial pneumonia (defined as a significant positive culture in sputum or BAL fluid of pathogenic bacteria or blood culture and sputum culture with the growth of the same microorganism), invasive pulmonary mycosis according to EORTC/MSG 2008, a viral infection caused by RSV, Influenza, Parainfluenza, Adenovirus or Rhinovirus detected by indirect immunofluorescence or PCR in nasopharyngeal swabs or BAL, and CMV pneumonia defined by shell vial detection or identification of intranuclear/intracytoplasmatic inclusion bodies.[23,24] Non-infectious etiologies could be alveolar hemorrhage (defined as more than 20% hemosiderin-loaded macrophages or bloody tube progression in BAL fluid in the absence of infection), congestive heart failure (defined as abnormal radiological images and clinical signs ameliorated by diuretic therapy), a pulmonary manifestation of hematological cancer (biopsy-proven), transfusion-related acute lung injury, engraftment syndrome (noncardiogenic pulmonary edema during neutrophil recovery) and graft-versus-host disease (clinical and laboratory or biopsy-proven).[26,27]
Complications during or following BAL were classified as minor (mild hypoxemia enhancement and self-limited hemorrhage) or major (severe hypoxemia, hemorrhage requiring specific intervention, arterial hypotension requiring vasopressor therapy or death). According to institutional protocols, patients with a platelet count lower than 50,000/mm3 received platelet infusion during the procedure.
Therapeutic modifications were defined as any change, addition or discontinuation of antibiotics, antifungal, or antiviral therapy according to BAL fluid findings.
Data were analyzed using descriptive statistics. Continuous variables were described according to their median, whereas categorical variables were described according to their number and percentage. For statistical analysis, Mann-Whitney U-test (for continuous variables) and Fischer’s exact test (for categorical variables) were used.
The Ethics Committee at our hospital approved the study. An informed consent form was obtained from each patient.
|Table 1. Patients’ basal characteristics (n= 96).|
PIs were diagnosed by CT-scan in 94 episodes (97.9%) and by X-ray in 2. Sixty-eight (72.3%) had bilateral infiltrates. Alveolar pattern was present in 36 cases (37.5%), ground-glass opacities in 42 (43.8%), nodular in 37 (38.5%) and “tree-in-bud” pattern in 21 (22.3%). There was more than one abnormal CT pattern in 42 cases (43.8%).
Results from non-invasive diagnostic methods are shown in Table 2. Sputum culture had the highest diagnostic yield (32%), followed by nasopharyngeal swab (18.8%), blood culture (7.3%), and serum galactomannan (5.8%). All urinary pneumococcal antigen tests performed were negative. Differences between positive tests and definitive diagnosis are explained by co-infection (for the case of nasopharyngeal swabs), the clinical relevance of microbiological findings (for sputum cultures), or false-positive results according to clinical and radiological criteria (for serum galactomannan).
|Table 2. Non-invasive diagnostic methods used.|
As far as CMV infection is concerned, serum viral load was performed in 8 patients with risk factors for CMV infection,[28-30] 2 of whom were positive. No BAL Shell vial or pathology sample yielded positive results for CMV infection.
BAL was performed in 47 (49%) episodes, 40 of which (85%) occurred in a new fashion, and 38 of which (81%) were under an empirical antimicrobial therapy. There was a microbiological diagnostic yield of 40.4% (19 positive cultures, 5 of which with more than one pathogen identified). The results are shown in Table 3. All positive BAL results were considered diagnostic. BAL was not performed in 49 cases for the following reasons: good response to empirical treatment started at 48h (51%), a serious clinical condition making procedure unsafe (18.4%), non-invasive diagnosis obtained (22.4%) and non-infectious alternative diagnosis (8.2%). BAL was more frequently performed in patients with acute leukemias and under fludarabine regimes.
|Table 3. BAL microbiologic results.|
We did not find a significant correlation between pulmonary imaging abnormalities and etiologic diagnostic yield (Table 4); however, noteworthy is the fact that the majority of BAL performed was in cases presenting with nodular lesions. BAL fluid results led to therapeutic changes in antimicrobial drug and its duration in 27 episodes (Table 5). In those cases evidencing negative BAL, and based on the BAL fluid galactomannan negative results, 4 antifungal treatments could be discontinued. Seven wide-spectrum antibiotic treatments against multi-resistant organisms were also discontinued. All patients (n=11) in which treatment was discontinued had a favourable outcome with the resolution of pulmonary infection. As far as outcome is concerned, 16 (34%) patients had oxygen saturation lower than 90%, and 25 (53.2%) had a platelet count <50,000/mm3 (3 of which had <10,000/mm3) at the time of bronchoscopy. Breath rate and oxygen saturation were 20 (12-26) vs 20 (12-26), (p = 0.41) and 95 (64-100) vs 95 (86-98), (p = 0.74) before and after bronchoscopy, respectively. BAL-related complications consisted of two minor (mild hypoxemia) and one major (respiratory failure requiring mechanical ventilation assistance) events, with no procedure-related deaths.
|Table 4. Predominant pulmonary infiltrate and diagnostic yield.|
|Table 5. Therapeutic changes following BAL results.|
Of all the 97 PIs herein included, a definitive etiology was obtained in 41 (42.7%) cases (Table 6). The following results were obtained: infection in 33 cases (80.5%), fluid overload in 4 (9.7%), alveolar hemorrhage in 2 (4.8%), underlying hematological malignancy in 1 (2.5%) and graft-versus-host-disease in 1 (2.5%). Fourteen patients required ICU admission, and thirteen (13.5%) died during the 30 days following the initial respiratory event, 6 of them being directly related to PI event.
|Table 6. Etiology of pulmonary infiltrates in patients with a definitive diagnosis.|
In four cases, Aspergillus galactomannan in BAL was negative, leading to discontinuation of antifungal treatment. Aspergillus galactomannan in BAL is known to have an excellent negative predictive value.[21,32] Locally, we have found that Aspergillus spp was the most frequent mold isolate in immunosuppressed patients, whereas Zygomycetes accounted for less than 6 % of the cases.
In contrast with other reports,[34,35] we did not find significant differences in diagnostic yield according to pulmonary imaging patterns. We believe this may be, in part, explained by our low total cases number or by the lack of randomization according to radiographic findings.
BAL appeared to be safe in our cohort, with only 1 severe adverse event related to the procedure. 53.2% of cases had significant thrombocytopenia, and 34% had hypoxia at the time of BAL, with no procedure-related mortality. These numbers are lower than those reported in the literature.[12,17,36]
Non-invasive diagnostic methods led to 30 positive microbiological results, mainly respiratory virus-positive swabs or sputum culture. However, BAL was performed in 9 of these cases, mainly due to the high possibility of co-infections in this group of patients. Only 14 out of 96 cases could be diagnosed through non-invasive methods.
In the absence of serum galactomannan positive tests, positive galactomannan in BAL let to the diagnosis of pulmonary aspergillosis in a small number of patients. This finding is similar to previous reports evidencing a sensitivity gap of over 60% when comparing BAL fluid with positive serum tests.[38-40]
This study has many limitations. Firstly, the lack of randomization of patients undergoing BAL leads to probable selection bias towards the group of patients in which BAL was performed. However, no significant clinical differences were observed between patients. There was also a selection bias toward more immunosuppressed patients and specific imaging patterns since BAL was mainly performed in patients with a diagnosis of acute leukemia, those treated with fludarabine, and patients presenting nodular pulmonary lesions. Given the design of the study, the clinical outcome and management changes between groups of patients could not be compared.
The multidisciplinary approach to the management of these patients (including internists, oncologists, pneumologists, and infectious diseases specialists) leads to discrepancies in the usefulness of BAL in this setting. In a recent study, Marchesi et al. observed that a BAL-driven antimicrobial approach has a positive impact on clinical outcome and mortality.
We believe our findings enlarge the still scarce body of evidence that will help determine more precise algorithms for the diagnosis and treatment of pulmonary infiltrates in patients with hematological malignancies. Future comparative randomized studies are required to determine the actual impact of BAL and the timing of performance on the management of this complex group of patients.
- Sharma S, Nadrous HF, Peters SG, Tefferi A, Litzow
M, Aubry MC and Afesso B. Pulmonary complications in adult blood and
marrow transplant recipients: autopsy findings. Chest.
2005;128(3):1385-1392. https://doi.org/10.1378/chest.128.3.1385 PMid:16162733
CC, Czerlanis C, Forsythe S, Stiff PJ. Retrospective utility of
bronchoscopy after hematopoietic stem cell transplant. Bone Marrow
Transplant. 2006;38(10):693-698. https://doi.org/10.1038/sj.bmt.1705505 PMid:16980989
KA, King E, Rochester R, Woodard P, Handgretinger R and Hale G.
Diagnostic yield of bronchoalveolar lavage is low in allogeneic
hematopoietic stem cell recipients receiving immunosuppressive therapy
or with acute graft-versus-host disease: the St. Jude experience,
1990-2002. Biol Blood Marrow Transplant. 2007;13(7):831-837. https://doi.org/10.1016/j.bbmt.2007.03.008 PMid:17580261
DP, Baker AM, Hurd DD, Haponik EF. Bronchoscopic evaluation of
pulmonary infiltrates following bone marrow transplantation. Chest.
1997;111(1):135-141. Accessed May 25, 2014. https://doi.org/10.1378/chest.111.1.135 PMid:8996007
AF, Susla GM, O'Grady NP. Pulmonary infiltrates in the non-HIV-infected
immunocompromised patient: etiologies, diagnostic strategies, and
outcomes. Chest. 2004;125(1):260-271. https://doi.org/10.1378/chest.125.1.260 PMid:14718449
VR, Andersson BS, Lei X, Champlin RE, Kontoyiannis DP. Utility of early
versus late fiberoptic bronchoscopy in the evaluation of new pulmonary
infiltrates following hematopoietic stem cell transplantation. Bone
Marrow Transplant. 2010;45(4):647-655. https://doi.org/10.1038/bmt.2009.203 PMid:19684637
A, Agustí C, Jimenez P, Angrill J, Benito N, Danes C, Gonzalez J,
Rovira M, Pumarola T, Moreno A and Torres A. Pulmonary infiltrates in
non-HIV immunocompromised patients: a diagnostic approach using
non-invasive and bronchoscopic procedures. Thorax. 2001;56(5):379-387. https://doi.org/10.1136/thorax.56.5.379 PMid:11312407 PMCid:PMC1746047
T, Rana S, Edell ES. Safety, diagnostic yield, and therapeutic
implications of flexible bronchoscopy in patients with febrile
neutropenia and pulmonary infiltrates. Mayo Clin Proc.
2005;80(11):1414-1420. https://doi.org/10.4065/80.11.1414 PMid:16295020
E, Mokart D, Rabbat A, Pene F, Kouatchet A, Bruneel F, Vincent F,
Hamidfar R, Moreau D, Mohammedi I, Epinette G, Beduneau G, Castelain V,
de Lassence A, Grusson D, Lemiale V, Renard B, Chevret S and Schlemmer
B. Diagnostic bronchoscopy in hematology and oncology patients with
acute respiratory failure: prospective multicenter data. Crit Care Med.
2008;36(1):100-107. https://doi.org/10.1097/01.CCM.0000295590.33145.C4 PMid:18090351
G, Beinert T, Buchheidt D, Cornely OA, Einsela H, Heinz W, Heussel CP,
Kahl C, Kiehl M, Lorenz H, Hof H and Mattiuzzii G. Diagnosis and
antimicrobial therapy of lung infiltrates in febrile neutropenic
patients: Guidelines of the infectious diseases working party of the
German Society of Haematology and Oncology. Eur J Cancer.
2009;45(14):2462-2472. https://doi.org/10.1016/j.ejca.2009.05.001 PMid:19467584
P, Sandur S, Meli Y, Arroliga AC, Stoller JK, Mehta AC. Role of
flexible bronchoscopy in immunocompromised patients with lung
infiltrates. Chest. 2004;125(2):712-722. https://doi.org/10.1378/chest.125.2.712 PMid:14769756
CR, Lerner A, Baram M, Awsare BK. Utility of flexible bronchoscopy in
the evaluation of pulmonary infiltrates in the hematopoietic stem cell
transplant population -- a single center fourteen year experience. Arch
Bronconeumol. 2013;49(5):189-195. https://doi.org/10.1016/j.arbres.2012.11.012 PMid:23455477
H, Suh GY, Jeong B-H, Lim SY, Chung MP, Kwon OJ and Jeon K. Etiologies,
diagnostic strategies, and outcomes of diffuse pulmonary infiltrates
causing acute respiratory failure in cancer patients: a retrospective
observational study. Crit Care. 2013;17(4):R150. https://doi.org/10.1186/cc12829 PMid:23880212 PMCid:PMC4055964
D, Lehrnbecher T, Phillips B, Fisher BT, Zaoutis TE, Steinbach WJ,
Beyene J and Sung L. Bronchoalveolar lavage and lung biopsy in patients
with cancer and hematopoietic stem-cell transplantation recipients: a
systematic review and meta-analysis. J Clin Oncol. 2015;33(5):501-509. https://doi.org/10.1200/JCO.2014.58.0480 PMid:25559816
Couselo FA, Morero JL, Sánchez F, Dictar M, Zylberman M. [Pulmonary
infiltrates in cancer patients]. Medicina (B Aires).
2008;68(5):367-372. Accessed March 29, 2016.
Eiff M, Zühlsdorf M, Roos N, Thomas M, Büchner T, van de Loo J.
Pulmonary infiltrates in patients with haematologic malignancies:
clinical usefulness of non-invasive bronchoscopic procedures. Eur J
Haematol. 1995;54(3):157-162. Accessed March 28, 2016. https://doi.org/10.1111/j.1600-0609.1995.tb00207.x PMid:7720835
M, Rudert S, Hof H, Hehlmann R, Buchheidt D. Diagnostic yield of
bronchoscopy with bronchoalveolar lavage in febrile patients with
hematologic malignancies and pulmonary infiltrates. Ann Hematol.
2008;87(4):291-297. https://doi.org/10.1007/s00277-007-0391-6 PMid:17932672
F, Cattaneo C, Criscuolo M, Delia M, Dargenio M, Del Principe MI,
Spadea A, Fracchiolla NS, Melillo L, Perruccio K, Alati C, Russo D,
Garzia M, Brociner M, Cefalo M, Armiento D, Cesaro S, Decembrino N,
Mengarelli A, Tumbarello M, Busca A, Pagano L; Sorveglianza
Epidemiologica Infezioni nelle Emopatie (SEIFEM) Group. A
bronchoalveolar lavage-driven antimicrobial treatment improves survival
in hematologic malignancy patients with detected lung infiltrates: A
prospective multicenter study of the SEIFEM group. Am J Hematol.
2019;94(10):1104-1112. https://doi.org/10.1002/ajh.25585 PMid:31321791
AM, Chittaganpitch M, Baggett HC, Peret TC, Dare RK, Sawatwong P,
Thamthitiwat S, Areerat P, Samasuttipun W, Fisher J, MAloney SA, Erdman
DD and Olsen SJ. The burden of hospitalized lower respiratory tract
infection due to respiratory syncytial virus in rural Thailand. Cowling
BJ, ed. PLoS One. 2010;5(11):e15098. doi:10.1371/journal.pone.0015098. https://doi.org/10.1371/journal.pone.0015098 PMid:21152047 PMCid:PMC2994907
DN, Videla C, Ricarte C, Carballal G, Vidaurreta S, Echavarría M.
Rhinovirus detection by real-time RT-PCR in children with acute
respiratory infection in Buenos Aires, Argentina. Rev Argent Microbiol.
44(4):259-265. Accessed March 27, 2018.
J, Maertens V, Theunissen K, Meersseman W, Meersseman P, Meers S,
Verhoef G, Van Eldere and Lagrou K. Bronchoalveolar lavage fluid
galactomannan for the diagnosis of invasive pulmonary aspergillosis in
patients with hematologic diseases. Clin Infect Dis.
2009;49(11):1688-1693. https://doi.org/10.1086/647935 PMid:19886801
I, Hardak E, Zuckerman T, Geffen Y, Hoffman R, Yiglo M and Avivi I.
Does molecular analysis increase the efficacy of bronchoalveolar lavage
in the diagnosis and management of respiratory infections in
hemato-oncological patients? Int J Infect Dis. 2016;50:48-53. https://doi.org/10.1016/j.ijid.2016.07.011 PMid:27484225
Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T,
Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson
TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler
CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A,
Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR,
Zaoutis T, Bennett JE; European Organization for Research and Treatment
of Cancer/Invasive Fungal Infections Cooperative Group; National
Institute of Allergy and Infectious Diseases Mycoses Study Group
(EORTC/MSG) Consensus Group. Revised definitions of invasive fungal
disease from the European Organization for Research and Treatment of
Cancer/Invasive Fungal Infections Cooperative Group and the National
Institute of Allergy and Infectious Diseases Mycoses Study Group
(EORTC/MSG) C. Clin Infect Dis. 2008;46(12):1813-1821. https://doi.org/10.1086/588660 PMid:18462102 PMCid:PMC2671227
SW, Bowden RA, Hackman RC, Gleaves CA, Meyers JD, Clark JG. Rapid
detection of cytomegalovirus pulmonary infection by bronchoalveolar
lavage and centrifugation culture. Ann Intern Med. 1988;108(2):180-185.
Accessed January 31, 2018. https://doi.org/10.7326/0003-4819-108-2-180 PMid:2829672
GL, Thompson AB, Rennard SL, Linder J. Detection of cytomegalovirus in
bronchoalveolar lavage specimens. Spin amplification and staining with
a monoclonal antibody to the early nuclear antigen for diagnosis of
cytomegalovirus pneumonia. Chest. 1990;98(3):568-575. Accessed January
31, 2018. https://doi.org/10.1378/chest.98.3.568 PMid:2168309
MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, Palmer J,
Weisdorf D, Treister NS, Cheng GS, Kerr H, Stratton P, Duarte RF,
McDonald GB, Inamoto Y, Vigorito A, Arai S, Datiles MB, Jacobsohn D,
Heller T, Kitko CL, Mitchell SA, Martin PJ, Shulman H, Wu RS, Cutler
CS, Vogelsang GB, Lee SJ, Pavletic SZ, Flowers ME. National Institutes
of Health Consensus Development Project on Criteria for Clinical Trials
in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging
Working Group report. Biol Blood Marrow Transplant.
2015;21(3):389-401.e1. https://doi.org/10.1016/j.bbmt.2014.12.001 PMid:25529383 PMCid:PMC4329079
SA. The histological spectrum of pulmonary graft-versus-host disease in
bone marrow transplant recipients. Hum Pathol. 1995;26(6):668-675.
Accessed January 31, 2018. https://doi.org/10.1016/0046-8177(95)90174-4
- Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113(23):5711-5719. https://doi.org/10.1182/blood-2008-10-143560 PMid:19299333 PMCid:PMC2700312
P, Hakki M, Boeckh M. Cytomegalovirus in Hematopoietic Stem Cell
Transplant Recipients. Infect Dis Clin North Am. 2010;24(2):319-337. https://doi.org/10.1016/j.idc.2010.01.008 PMid:20466273
F, Pimpinelli F, Ensoli F, Mengarelli A. Cytomegalovirus infection in
hematologic malignancy settings other than the allogeneic transplant.
Hematol Oncol. June 2017. https://doi.org/10.1002/hon.2453 PMid:28660653
S, Di Pompeo C, Diarra M, Brisson H, Tissier S, Boulo M and Dorocher A.
Relationship between immunosuppression and intensive care unit-acquired
multidrug-resistant bacteria: a case-control study. Crit Care Med.
2007;35(5):1318-1323. https://doi.org/10.1097/01.CCM.0000261885.50604.20 PMid:17414081
ML, Filion C, Labbé AC, Roy J, Pépin J, Cadrin-Tourigny J, Carignan S,
Sheppard DC, Laverdière M. Clinical utility and prognostic value of
bronchoalveolar lavage galactomannan in patients with hematologic
malignancies. Diagn Microbiol Infect Dis. 2010;68(2):132-139. https://doi.org/10.1016/j.diagmicrobio.2010.03.017 PMid:20846585
Results for Surveillance of Invasive Mold Diseases (IMD) in Argentina
(AR), 2010-2013. M. C. Dignani, A. A. Cleveland, G. Davel, T. Chiller,
N. Refojo, S. Córdoba, A. Valledor, A. Laborde, M. L. Pereyra, I.
Roccia-Rossi, R. Jordán, F. Herrera, N. Tiraboschi, G. Guerrini, H.
Peretti, A. Zárate,J. Afeltra, A. Vila, L. Tula, C. Freuler, S.
López-Papucci, Register for Invasive Mycoses (REMIIN Group);53rd ICAAC
2013. Sep 10-13, Denver, CO. USA Abst# 1437
K, Simpson S. Association of bronchoalveolar lavage yield with chest
computed tomography findings and symptoms in immunocompromised
patients. Ann Thorac Med. 2013;8(3):153. https://doi.org/10.4103/1817-1737.114302 PMid:23922610 PMCid:PMC3731857
D, Hilbert G, Valentino R, Vargas F, Chene G, Bebear C, Allery A,
Pigneux A, Gbikpi-Benissan G, Cardinaud JP. Utility of fiberoptic
bronchoscopy in neutropenic patients admitted to the intensive care
unit with pulmonary infiltrates. Crit Care Med. 2000;28(7):2224-2230.
Accessed March 27, 2018. https://doi.org/10.1097/00003246-200007000-00007 PMid:10921544
M., Puxeddu E., Sarmati L., Paterno G., Fontana C., Nasso D., Pane G.,
De Bellis E., Palmieri R., Buzzati E., Meconi F., Laureana R., Casciani
P., Zizzari A.G., Rogliani P., de Fabritiis P., Maurillo L., Buccisano
F., Cantonetti M., Arcese W., Venditti A., Del Principe M.I.Diagnostic
performance and safety of bronchoalveolar lavage in thrombocytopenic
haematological patients for invasive fungal infections diagnosis: a
monocentric, retrospective experience. Mediterr J Hematol Infect Dis
2019, 11(1): e2019065, DOI: https://doi.org/10.4084/mjhid.2019.065 PMid:31700590 PMCid:PMC6827601
JR, Hiemenz JW, Jantz MA. How I manage pulmonary nodular lesions and
nodular infiltrates in patients with hematologic malignancies or
undergoing hematopoietic cell transplantation. Blood. 2012;
120(9):1791-1800. https://doi.org/10.1182/blood-2012-02-378976 PMid:22692506
T, Buchheidt D, Spiess B, Miethke T, Hofmann W-K, Reinwald M. Direct
comparison of galactomannan performance in concurrent serum and
bronchoalveolar lavage samples in immunocompromised patients at risk
for invasive pulmonary aspergillosis. Mycoses. 2016;59(2):80-85. https://doi.org/10.1111/myc.12434 PMid:26627577
MD, Amutio E, García-Ruiz JC, Pontón J. [Usefulness of galactomannan
detection in the diagnosis and follow-up of hematological patients with
invasive aspergillosis]. Rev Iberoam Micol. 2003;20(3):103-110. http://www.ncbi.nlm.nih.gov/pubmed/15456366. Accessed March 21, 2016.
J, Catalan M, del Palacio-Peréz-Medel A, Lora D, Montejo JC, Cuetara
MS, Moragues MD, Ponton J and del Palacio A. A prospective comparison
of galactomannan in bronchoalveolar lavage fluid for the diagnosis of
pulmonary invasive aspergillosis in medical patients under intensive
care: comparison with the diagnostic performance of galactomannan and
of (1→ 3)-β-d-glucan. Clin Microbiol Infect. 2011;17(7):1053-1060. https://doi.org/10.1111/j.1469-0691.2010.03357.x PMid:20825441
AS, Chatterjee A, Khan II, Conforti JF, Haponik E. Survey of academic
pulmonologists, oncologists, and infectious disease physicians on the
role of bronchoscopy in managing hematopoietic stem cell
transplantation patients with pulmonary infiltrates. J Bronchology
Interv Pulmonol. 2014;21(1):32-39. https://doi.org/10.1097/LBR.0000000000000042 PMid:24419184